Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 549-554

  Chang, Peter Mu Hsin ^a,b   Chen, Po Min ^a,b   Hsieh, Shie Liang ^a   Tzeng, Cheng Hwai ^a,b   Liu, Jin Hwang ^a,b   Chiou, Tzeon Jye ^a,b   Wang, Wei Shu ^a,b   Yen, Chueh Chuan ^a,b   Gau, Jyh Pyng ^a,b   Yang, Muh Hwa ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Diffuse large B cell lymphoma; Prognosis; Soluble decoy receptor 3

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DECOY RECEPTOR 3; DOXORUBICIN; FAS LIGAND; IMMUNOGLOBULIN LIGHT CHAIN; PREDNISONE; TUMOR NECROSIS FACTOR RECEPTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; TNFRSF6B PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; LARGE CELL LYMPHOMA; LEUKEMIA CELL LINE; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SECRETION; RAJI CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LYMPHOMA; TUMOR CELL; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 54849186400     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000039     Document Type: Article

References (32)

1. Department of Health, the Executive Yuan. Cancer registry annual report in Taiwan area, Department of Health, Executive Yuan, R.O.C., 2004.
2. Armitage JO and Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16: 2780-2795, 1998.
3. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006, 1993.
4. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.
5. Abramson JS and Shipp MA: Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106: 1164-1174, 2005.
6. Muschen M, Rajewsky K, Kronke M and Kuppers R: The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol 23: 75-80, 2002.
7. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501, 2001.
8. Pitti RM, Marsters SA, Lawrence DA, et al: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703, 1998.
9. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and Kwon BS: A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274: 13733-13736, 1999.
10. Migone T, Zhang J, Luo X, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
11. Bai C, Connolly B, Metzker ML, et al: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97: 1230-1235, 2000.
12. Nagata S and Goldstein P: Fas death factor. Science 267: 1449-1456, 1995.
13. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T and Nagata S: Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6: 1567-1574, 1994.
14. Itoh, N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991.
15. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B and Kalthoff H: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58: 1741-1749, 1998.
16. O'Connell J, O'Sullivan GC, Collins JK and Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082, 1996.
17. Li H, Zhang L, Lou H, et al: Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus Am J Clin Pathol 124: 282-287, 2005.
18. Takahama Y, Yamada Y, Emoto K, et al: The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5: 61-68, 2002.
19. Roth W, Isenmann S, Nakamura M, et al: Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61: 2759-2765, 2001.
20. Shen HW, Gan SL, Wu YL and Peng SY: Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 11: 5926-5930, 2005.
21. Tsuji S, Hosotani R, Yonehara S, et al: Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 106: 17-25, 2003.
22. Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M and Kikuchi M: Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett 160: 89-97, 2000.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
24. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994, 1993.
25. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-1861, 2007.
26. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
27. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947, 2002.
28. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282, 2004.
29. Richardson DS and Johnson SA: Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 11: 201-223, 1997.
30. Belaud-Rotureau MA, Durrieu F, Labroille G, et al: Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment. Leukemia 14: 1266-1275, 2000.
31. Wieder T, Essmann F, Prokop A, et al: Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97: 1378-1387, 2001.
32. Wu XX, Mizutani Y, Kakehi Y, et al: Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 60: 2912-2918, 2000.